The European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric ...
Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy ...
GlobalData on MSN8h
EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapyThe European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...
Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma: Princeton, New Jersey Monday, ...
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback